entertainment -WSS

entertainment

author：knowledge 2025-09-29 01:06:34 - browse：28716

Christine Kao/STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves. So when new market developments threaten to diminish or wipe away that revenue stream, PBMs find crafty ways to keep as much of those dollars as possible — often at the expense of employers.

One such case occurred last year, when a wave of Humira biosimilars entered the market and drug companies slashed the list prices of their insulin products. CVS Caremark, the PBM owned by CVS Health that oversees the prescription drug benefits of 103 million people, told its employer clients that it anticipated “more lower-cost products (including specialty biosimilars) may become preferred products” on its lists of approved drugs for 2024, according to documents obtained by STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Bird flu researchers hone in on Finland’s mink farms

focus

WSS

Cord blood banking comes at a high cost to babies

Novo Nordisk touts Wegovy study, but still struggling with supply

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Be careful with at

BMS, looking to build heart drug business, turns to AI for diagnosis

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

hotspot

entertainment

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Anesthesiologist group: stop taking Ozempic before surgery

After Optum profits sink, UnitedHealth makes changes

Tori Bowie and the unacceptable rates of Black maternal death

Illinois Supreme Court finds assault weapons ban constitutional

Medicare details structure of new drug price negotiation program

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

After affirmative action ruling, medical educators look to 'holistic review'

Patients, digital health players weigh in on FTC's data privacy plan

hotspot

Ionis drug prevents swelling attacks due to hereditary angioedema

How to increase colonoscopy rates? Looks like an AI can help

What to know about the judge who will handle the Trump case

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

BMS, looking to build heart drug business, turns to AI for diagnosis

entertainment

focus

Wikipedia

entertainment